Effect of potassium concentration and ouabain on the renal adaptation to potassium depletion in isolated perfused rat kidney

1986 ◽  
Vol 64 (11) ◽  
pp. 1427-1433 ◽  
Author(s):  
Daniel B. Ornt

Renal adaptation for potassium (K) conservation has been demonstrated in isolated perfused kidneys from rats within 3 days of K depletion and appears to be independent of aldosterone and sodium excretion. This study was designed to investigate whether the renal adaptation for K conservation is independent of ambient [K] and renal tissue levels of K and whether ouabain may have effects on K excretion, which are in constrast to the effects on K excretion in normal animals, in the first study, rats K depleted for 3 days received 2500 μequiv. KCl intraperitoneally, while other K-depleted rats and a group of control diet animals received intraperitoneal H2O alone to determine whether simple restoration of K deficits would reverse the renal adaptation for K conservation. Intraperitoneal KCl increased plasma [K] and kidney tissue K significantly within 3 h in the K-repleted group compared with the K-depleted rats. Isolated kidneys were perfused from the three groups of rats 3 h after intraperitoneal injection. Despite K repletion in vivo, perfused kidneys from the K-repleted group still had significantly decreased K excretion (1.28 ± 0.085 μequiv./min) compared with controls (2.05 ± 0.291 μequiv./min), and K excretion was still not different from the K-depleted group (0.57 ± 0.134 μequiv./min). However, fractional K excretion by the kidneys from K-repleted rats was increased above K-depleted kidneys (0.48 ± 0.051 vs. 0.18 ± 0.034, p < 0.01). Despite the increased renal tissue K in K-repleted kidneys at the start of perfusion (285 ± 5.1 vs. 257 ± 5.4 μequiv./g), by the end of the perfusion tissue K in perfused kidneys was identical in all three groups. In the second study, isolated kidneys were perfused from 3-day K-depleted or control rats with either 2 or 6 mM [K] in the perfusate. Isolated kidneys adapted to 3 days of K depletion excreted less K at both 2 and 6 mM [K] compared with controls at the same ambient [K]. The linear relationship of K excretion to perfusate [K] was significantly different in controls compared with low K adapted kidneys (p < 0.001). Finally, when 10−4 M ouabain was added after 60 min of perfusion in kidneys from control diet rats, there was a sodium diuresis and fractional K excretion decreased significantly (0.55 ± 0.043 to 0.32 ± 0.044, p < 0.01). However, in low K adapted kidneys, ouabain had no effect on fractional K excretion (0.020 ± 0.051 to 0.18 ± 0.038) despite a similar increase in sodium excretion. Perfusions of kidneys from 3-day K-depleted rats at 4 × 10−3 M ouabain gave similar results, showing no change in fractional K excretion. Low K adaptation to K depletion developed within 3 days and was not totally abolished by acute K repletion. Maneuvers that favored either a decrease in renal tissue K or an increase in tissue K did not reverse low K adaptation, although renal tissue K levels did alter the rate of K excretion in both controls and K-depleted kidneys. Therefore, a reduction in tissue K was clearly not the sole mediator of renal K conservation. Finally, the markedly different response of low K adapted kidneys to ouabain compared with controls strongly suggests a mechanism for K reabsorption that developed within 3 days of K depletion and is ouabain sensitive.

1987 ◽  
Vol 252 (2) ◽  
pp. F331-F337 ◽  
Author(s):  
W. Lieberthal ◽  
M. L. Vasilevsky ◽  
C. R. Valeri ◽  
N. G. Levinsky

Interactions between antidiuretic hormone (ADH) and renal prostaglandins in the regulation of sodium reabsorption and urinary concentrating ability were studied in isolated erythrocyte-perfused rat kidneys (IEPK). In this model, hemodynamic characteristics are comparable to those found in vivo, and tubular morphology is preserved throughout the period of perfusion. [Deamino]-D-arginine vasopressin (dDAVP) markedly reduced fractional sodium excretion (FE Na) in the IEPK from 3.5 +/- 0.6 to 0.45 +/- 0.14%. After indomethacin, FE Na fell still further to 0.08 +/- 0.02%. In the absence of dDAVP indomethacin had no effect on sodium excretion; FE Na was 2.4 +/- 0.6% in control and 2.0 +/- 0.4% in indomethacin-treated groups. dDAVP increased urine osmolality in the IEPK to 741 +/- 26 mosmol/kg. When prostaglandin synthesis was blocked with indomethacin, urinary osmolality increased further to 1,180 +/- 94 mosmol/kg. In isolated kidneys perfused without erythrocytes (IPK), dDAVP decreased FENa from 14.5 +/- 1.8% to 9.6 +/- 1.2%; addition of indomethacin had no further effect. dDAVP increased urine osmolality only modestly to 350 +/- 12 mosmol/kg in the IPK and indomethacin did not increase concentrating ability further (342 +/- 7 mosmol/kg). Thus the IEPK (unlike the IPK) can excrete a markedly hypertonic urine in response to ADH. ADH also enhances tubular reabsorption of sodium in the IEPK. Prostaglandins inhibit both these actions of ADH but do not directly affect sodium excretion in the absence of the hormone.


1983 ◽  
Vol 245 (3) ◽  
pp. F329-F338 ◽  
Author(s):  
D. B. Ornt ◽  
R. L. Tannen

Renal potassium conservation occurs within 3 days of potassium deprivation by a mechanism that appears to be independent of mineralocorticoids and sodium and anion excretion. To examine whether the mechanism involves an intrinsic renal adaptation, urinary potassium excretion was measured in isolated perfused kidneys from rats maintained on a normal or K+-free diet for 3 days. Perfusions were carried out with a K+ concentration that averaged 3.5 mM and with glucose (5 mM) as the only substrate. Both absolute (UKV) and fractional K+ excretion (FEK) were substantially less in kidneys from animals on K+-free diets compared with controls. These differences in K+ excretion were not explained by changes in GFR, urine flow rate, urine pH, or sodium, chloride, or ammonium excretion. The K+ content of renal tissue was not different in the perfused and nonperfused kidneys from rats receiving K+-free diets compared with controls. Suppression of K+ excretion by amiloride (10(-4) M) suggested that, as in vivo, tubular secretion of K+ in the perfused normal kidney accounts for 90% of the urinary K+ excretion and that tubular K+ secretion is reduced in isolated kidneys from animals on a K+-free diet. Further studies of isolated kidneys from adrenalectomized (ADX) rats receiving aldosterone and dexamethasone replacement and fed a normal or K-free diet also revealed significantly lower UKV and FEK in kidneys from animals on K+-free diets. K+ content of renal tissue was not different in the ADX animals on a K+-free diet compared with ADX rats on normal K+ intake. These studies indicate that within 72 h of dietary K+ deprivation an intrinsic renal adaptive process to conserve potassium is activated that is independent of renal potassium content, aldosterone, and urinary factors that can alter K+ excretion such as flow, pH, ammonium, sodium, and anions. This regulatory mechanism, which has a substantial influence on potassium excretion, remains to be elucidated.


1984 ◽  
Vol 62 (3) ◽  
pp. 272-276 ◽  
Author(s):  
Andrew D. Baines ◽  
Rosa Drangova

We used isolated perfused rat kidneys to examine dopamine (DA) production and its relation to renal function. Both innervated and chronically surgically denervated kidneys perfused with a solution containing neither albumin nor tyrosine, excreted 0.2 ± 0.1 ng DA∙min−1∙g wet weight−1 during the 10-min collection period between 30 and 40 min after starting perfusion. When perfused with 6.7% albumin, without tyrosine, innervated kidneys excreted 1.0 ± 0.06 ng DA∙min−1∙g−1 and denervated kidneys excreted 1.0 ± 0.07 DA∙min−1∙g−1. When 0.03 mM tyrosine was included in the albumin perfusate, innervated kidneys excreted 1.2 ± 0.1 ng DA∙min−1∙g−1 (p < 0.1). Under these conditions DA excretion continued for at least 100 min at which time it was 0.6 ng∙min−1∙g−1 and 86 ng/g kidney weight had been excreted. Denervated kidneys perfused with albumin + tyrosine excreted 0.9 ± 0.13 ng DA∙min−1∙g−1. Renal stores of free DA, conjugated DA, and dihydroxyphenylalanine (DOPA) could have provided at the most 30 ng/g of DA. Carbidopa inhibited DA excretion completely. DA excretion did not correlate with renal vascular resistance, inulin clearance, or fractional sodium excretion. In summary, nonneural tissue in isolated perfused kidneys produced DA at the same rate as denervated kidneys in vivo. Less than one-third of the DA produced by isolated kidneys could have come from intrarenal stores of DOPA, free DA, and conjugated DA; the rest was synthesized from unknown precursors. Circulating DOPA and tyrosine were not the DA precursors, but albumin was required to obtain production rates similar to those in vivo. Nonneuronal DA production did not influence renal hemodynamics, glomerular filtration rate (GFR), or sodium excretion.


1989 ◽  
Vol 256 (5) ◽  
pp. F776-F779
Author(s):  
J. D. Firth ◽  
A. E. Raine ◽  
J. G. Ledingham

Studies were performed to determine the effects of elevation of renal venous pressure on sodium excretion by the isolated perfused rat kidney in the presence and absence of a specific V2-receptor agonist, 1-des-amino-8-D-arginine vasopressin (dDAVP), at a concentration (1 ng/ml) expected to have maximal antidiuretic activity but minor vasopressor action. In either the presence or absence of dDAVP, increments in venous pressure led to falls in perfusate flow rate and glomerular filtration rate, which became significant at an imposed pressure greater than or equal to 18.75 mmHg. In the absence of dDAVP, absolute sodium excretion fell as venous pressure increased, and there was a negative correlation between fractional sodium excretion (FENa) and renal venous pressure (RVP) within each experiment and when all data points were combined: FENa = 3.46-0.072RVP (r = -0.608, P less than 0.01). In contrast, in the presence of dDAVP, absolute sodium excretion was unchanged, and in four of five experiments FENa rose as venous pressure increased (in one it remained unchanged). Linear regression analysis of all data points showed a positive correlation between FENa and RVP: FENa = 1.27 + 0.127RVP (r = 0.392, P less than 0.05). The slopes of the two regression lines were significantly different (P less than 0.001). It is postulated that this effect of dDAVP may be mediated via changes in the distal tubular pressure response to elevation of RVP. Such an effect of vasopressin could explain the observation that the response to renal vein constriction in vivo is dependent on volume status.


2020 ◽  
Vol 12 (10) ◽  
pp. 1185-1191
Author(s):  
Haixia Liu ◽  
Wenwen Huang ◽  
Xinli Han ◽  
Qihang Ma

Ligusticum chuanxiong can relieve the degree of renal fibrosis. However, the specific mechanism of Ligusticum chuanxiong to improve renal fibrosis is not yet clear. A unilateral ureteral obstruction was used to construct a rat renal fibrosis model. The rats were treated with 20 mg/kg and 40 mg/kg of Ligusticum chuanxiong. Four weeks after treatment, blood was collected from the rats, and the rats were sacrificed. Blood urea nitrogen (BUN), serum creatinine (Scr), kidney tissue malondialdehyde (MDA), and superoxide dismutase (SOD) levels were detected. Hematoxylin–eosin staining was used to observe the pathological rat kidney changes. The renal tissue smooth muscle actin (α-SMA) was detected by immunohistochemistry. Nrf2 and HO-1 levels were determined by PCR using nano-magnetic beads. The results showed BUN, Scr, and MDA levels reduced, while SOD levels were elevated in Ligusticum chuanxiong-treated rats, compared to model rats (P < 0.05). These effects were more dramatic in Ligusticum chuanxiong high dose (HD) rats compared to Ligusticum chuanxiong low dose (LD) rats. Additionally, Nrf2 and HO-1 levels were elevated in Ligusticum chuanxiong-treated rats (P < 0.05). These effects were also more dramatic in HD rats compared to LD rats. These findings indicated that Ligusticum chuanxiong early administration can reduce renal fibrosis in rats by stimulating the Nrf2/HO-1 pathway.


1996 ◽  
Vol 85 (6) ◽  
pp. 1454-1461. ◽  
Author(s):  
Ramaswamy A. Iyer ◽  
M. W. Anders

Background 2-(Fluoromethoxy)-1,1,3,3,3-pentafluoro-1-propene (compound A) is a fluorinated alkene formed by the degradation of sevoflurane in the anesthesia circuit. Compound A is toxic to the kidneys in rats and undergoes glutathione-dependent metabolism in vivo. Several nephrotoxic halogenated alkenes also undergo cysteine conjugate beta-lyase-dependent biotransformation. These experiments were designed to test the hypothesis that cysteine S-conjugates of compound A undergo beta-lyase-dependent biotransformation. Methods S-[2-(Fluoromethoxy)-1,1,3,3,3-pentafluoropropyl]-L-cysteine 4, S-[2-(fluoromethoxy)-1,3,3,3-tetrafluoro-1-propenyl]-L-cysteine 5, and S-(2-chloro-1,1,2-trifluoroethyl)-L-cysteine 11 were incubated with rat, human, and nonhuman primate (cynomolgus, rhesus, and marmoset) kidney cytosol and mitochondria. beta-Lyase activity was determined by measuring pyruvate formation. Results Compound A-derived conjugates 4 and 5 as well as conjugate 11, a positive control, were substrates for cytosolic and mitochondrial beta-lyase from human, nonhuman primate, and rat kidney. For all substrates, beta-lyase activity was highest in the rat and lowest in the human and was higher in cytosol than in mitochondria. Conjugate 11 was a much better substrate than conjugates 4 or 5. The biotransformation of conjugates 4, 5, and 11 was inhibited by the beta-lyase inhibitor (aminooxy)acetic acid and was stimulated by the amino group acceptor 2-keto-4-methylthiolbutyric acid, indicating a role for beta-lyase. Conclusions These data confirm the presence of beta-lyase activity in human and rat kidney and show that activity is also present in kidney tissue from nonhuman primates. The data also show that compound A-derived conjugates 4 and 5 undergo beta-lyase-catalyzed biotransformation. beta-Lyase activity in rat and nonhuman primate kidney tissue was 8 to 30 times and one- to three times, respectively, higher than in human kidney tissue.


Hypertension ◽  
2017 ◽  
Vol 70 (suppl_1) ◽  
Author(s):  
John D Imig ◽  
Md A Khan ◽  
Adeniyi M Adebesin ◽  
John R Falck

Epoxyeicosatrienoic acid (EET) analogs have exceptional therapeutic potential to combat cardiovascular and kidney diseases. EET analogs combat damage in acute and chronic kidney disease models. Biological actions attributed to EET analogs such as vasodilation, anti-inflammation, anti-apoptosis, and anti-fibrosis are ideally suited to treat kidney diseases. Although EET analogs have performed well in several in vivo models, targeted delivery of EET analogs to the kidney can be reasonably expected to reduce the level of drug needed to achieve a therapeutic effect in the kidney and obviate possible side effects. For EET analog kidney-targeted delivery, we conjugated an EET analog to folic acid because there is a high concentration of folate receptors in renal tissue. The EET analog was conjugated to folic acid via a PEG-diamine linker. Next, we compared the kidney targeted EET analog, EET-F01, to a well-studied EET analog, EET-A. EET-A or EET-F01 was infused i.v. (10mg/kg/hr) for 6 hours via the rat jugular vein. Plasma and kidney tissue were collected and EET-A or EET-F01 measured by LC-MS-MS. EET-A plasma level was 1.6 ng/mL, but EET-A was undetectable in the kidney. On the other hand, EET-F01 was 6.5 ng/mL in plasma and 26.7 ng/mL in kidney tissue. These data demonstrate that EET-F01 targets the kidney. Experiments were conducted to compare EET-F01 and EET-A to decrease cisplatin-induced nephrotoxicity. A single injection of cisplatin (7 mg/kg ip) was administered to WKY rats treated with vehicle, EET-A (10 mg/kg ip) or EET-F01 (20 mg/kg or 2 mg/kg ip) for five days. Cisplatin increased BUN (125 ± 11 mg/dL) and NAG (12 ± 4 IU/L) compared to control (36 ± 9 mg/dL and 4 ± 1 IU/L). EET-F01 was as effective as EET-A in decreasing BUN, NAG, and renal histological injury five days following cisplatin administration. Despite it almost 2x-greater molecular weight compared with EET-A, EET-F01 was effective in lowering BUN and NAG at 20 mg/kg/d and at a 10-fold lower dose of 2 mg/kg/d. These data clearly demonstrate that EET-F01 targets the kidney and allows for a lower effective dose. In conclusion, we have developed a kidney targeted EET analog, EET-F01, that demonstrates excellent potential as a therapeutic for kidney diseases.


1985 ◽  
Vol 229 (2) ◽  
pp. 399-408 ◽  
Author(s):  
W G Haser ◽  
R A Shapiro ◽  
N P Curthoys

A phosphate-dependent glutaminase was purified 1200-fold from rat brain. In the absence of a polyvalent anion, the glutaminase exists as an inactive protomer which has an estimated Mr of 126000. The addition of 100mM-phosphate causes maximal activation and a dimerization (Mr 249000) of the glutaminase. The phosphate activation is sigmoidal, with a K0.5 of 25mM and a Hill coefficient (h) of 1.5 Glutamate inhibition is competitive with respect to glutamine and is decreased by increasing the concentration of phosphate. Phosphate also decreases the Km for glutamine. The purified glutaminase contains a predominant peptide (Mr 65000) and a minor peptide (Mr 68000) that are present in an approximate ratio of 4:1 respectively. The glutaminase immunoprecipitated from freshly solubilized brain tissue or from synaptosomal and non-synaptosomal brain mitochondria contains the same distribution of the two peptides. In contrast, the glutaminase purified from rat kidney contains five to seven peptides that range in Mr value from 59000 to 48000, and immunoprecipitates derived from freshly solubilized renal tissue contain only the Mr-65000 peptide. Partial proteolysis and size fractionation of the three immunoprecipitated peptides indicate that they are structurally related. The series of peptides characteristic of the purified renal glutaminase is generated on storage of the solubilized extract of kidney tissue. The glutaminase contained in the solubilized brain extract is not degraded unless a renal extract is added. Thus the difference in the pattern of peptides associated with the two purified enzymes is due to an endogenous renal proteinase that is not present in brain.


1983 ◽  
Vol 244 (6) ◽  
pp. F633-F638
Author(s):  
H. E. Abboud ◽  
T. P. Dousa

Recent in vivo studies indicated that adenosine has a profound effect on glomerular dynamics and renal circulation. Because its effect in nonrenal tissues is frequently mediated by adenosine 3',5'-cyclic monophosphate (cAMP), we examined adenosine's effect on cyclic nucleotides in rat kidney. Incubation of tissue slices from renal cortex or medulla with 0.1 mM adenosine resulted in marginal or no increase in cAMP. In isolated glomeruli, adenosine caused a marked and dose-dependent (10(-6) to 10(-4) M) increase in cAMP accumulation. Inosine, a deaminated metabolite of adenosine, had no effect on cAMP levels in glomeruli. No distinct effect of adenosine on cAMP was observed in cortical tubules under the same testing conditions. An increase in cAMP levels in glomeruli elicited by adenosine was blocked by theophylline, a known inhibitor of adenosine receptors. In contrast, theophylline enhanced rather than decreased the stimulation of cAMP accumulation in glomeruli by serotonin. Dipyridamole, a proposed inhibitor of cellular uptake of adenosine, did not inhibit but rather enhanced cAMP accumulation in glomeruli in response to adenosine. In the present experiments adenosine did not influence guanosine 3',5'-cyclic monophosphate levels in either glomeruli or other tested preparations of renal tissue. These results provide the first experimental evidence that adenosine stimulates cAMP accumulation in glomeruli and suggest that this effect is probably due to action on the adenosine receptor on the cell surface. Our observations raise the possibility that some of the effects of adenosine in glomerular cells may be mediated via cAMP accumulation.


1990 ◽  
Vol 258 (5) ◽  
pp. F1266-F1272 ◽  
Author(s):  
W. Lieberthal ◽  
A. M. Sheridan ◽  
C. R. Valeri

We have examined the effect of atrial natriuretic factor (ANF) administered with and without mannitol on renal function following ischemic injury in both the isolated erythrocyte-perfused rat kidney and in the rat in vivo. ANF, administered alone after 25 min ischemia in the isolated kidney, reversed postischemic vasoconstriction but did not improve glomerular filtration rate (GFR). Mannitol alone had no effect on either renal vascular resistance or GFR. However, in isolated kidneys treated with the combination of both ANF and mannitol following reflow, GFR (0.65 +/- 0.04 ml.min-1.g-1) was markedly improved compared with GFR in the untreated ischemia group (0.20 +/- 0.04 ml.min-1.g-1) and was not different from GFR in the nonischemic controls (0.68 +/- 0.05 ml.min-1.g-1). Comparable results were obtained in studies performed in vivo. In rats subjected to 45 min ischemia, GFR (0.15 +/- 0.05 ml/min) was reduced compared with the GFR in sham-operated animals (0.95 +/- 0.07 ml/min). ANF or mannitol administered alone following ischemia and reflow did not improve GFR compared with the untreated ischemic group. However, in rats subjected to ischemia and treated with a combination of ANF and mannitol postreflow, GFR (0.69 +/- 0.10 ml/min) was 4.6-fold higher than GFR in the untreated ischemic group. Thus the combination of ANF and mannitol appear to act synergistically to improve GFR following ischemic injury.


Sign in / Sign up

Export Citation Format

Share Document